tetano
Editor, Senior Moderator
J Antimicrob Chemother. 2012 Mar 30. [Epub ahead of print]
Prognosis of hospitalized patients with 2009 H1N1 influenza in Spain: influence of neuraminidase inhibitors.
Delgado-Rodr?guez M, Castilla J, Godoy P, Mart?n V, Soldevila N, Alonso J, Astray J, Baricot M, Cant?n R, Castro A, G?nz?lez-Candelas F, Mayoral JM, Quintana JM, Pumarola T, Tamames S, S?ez M, Dom?nguez A; on behalf of the CIBERESP Cases and Controls in Pandemic Influenza Working Group.
Collaborators (126)
Source
Universidad de Ja?n, Campus de las Lagunillas, 23071 Ja?n, Spain.
Abstract
BACKGROUND:
The H1N1 influenza pandemic strain has been associated with a poor prognosis in hospitalized patients. The present report evaluates the factors influencing prognosis.
METHODS:
A total of 813 patients hospitalized with H1N1 influenza in 36 hospitals (nationwide) in Spain were analysed. Detailed histories of variables preceding hospital admission were obtained by interview, validating data on medications and vaccine with their attending physicians. Data on treatment and complications during hospital stay were recorded. As definition of poor outcome, the endpoints of death and admission to intensive care were combined; and as a further outcome, length of stay was used.
RESULTS:
The mean age was 38.5 years (SD 22.8 years). There were 10 deaths and 79 admissions to intensive care (combined, 88). The use of neuraminidase inhibitors was reported by 495 patients (60.9%). The variables significantly associated with a poor outcome were diabetes (OR = 2.21, 95% CI = 1.21-4.02), corticosteroid therapy (OR = 3.37, 95% CI = 1.39-8.20) and use of histamine-2 receptor antagonists (OR = 2.68, 95% CI = 1.14-6.36), while the use of neuraminidase inhibitors (OR = 0.57, 95% CI = 0.34-0.94) was protective. Neuraminidase inhibitors within the first 2 days after the influenza onset reduced hospital stay by a mean of 1.9 days (95% CI = 4.7-6.6).
CONCLUSIONS:
The use of neuraminidase inhibitors decreases the length of hospital stay and admission to intensive care and/or death.
PMID:
22467633
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/22467633
Prognosis of hospitalized patients with 2009 H1N1 influenza in Spain: influence of neuraminidase inhibitors.
Delgado-Rodr?guez M, Castilla J, Godoy P, Mart?n V, Soldevila N, Alonso J, Astray J, Baricot M, Cant?n R, Castro A, G?nz?lez-Candelas F, Mayoral JM, Quintana JM, Pumarola T, Tamames S, S?ez M, Dom?nguez A; on behalf of the CIBERESP Cases and Controls in Pandemic Influenza Working Group.
Collaborators (126)
Source
Universidad de Ja?n, Campus de las Lagunillas, 23071 Ja?n, Spain.
Abstract
BACKGROUND:
The H1N1 influenza pandemic strain has been associated with a poor prognosis in hospitalized patients. The present report evaluates the factors influencing prognosis.
METHODS:
A total of 813 patients hospitalized with H1N1 influenza in 36 hospitals (nationwide) in Spain were analysed. Detailed histories of variables preceding hospital admission were obtained by interview, validating data on medications and vaccine with their attending physicians. Data on treatment and complications during hospital stay were recorded. As definition of poor outcome, the endpoints of death and admission to intensive care were combined; and as a further outcome, length of stay was used.
RESULTS:
The mean age was 38.5 years (SD 22.8 years). There were 10 deaths and 79 admissions to intensive care (combined, 88). The use of neuraminidase inhibitors was reported by 495 patients (60.9%). The variables significantly associated with a poor outcome were diabetes (OR = 2.21, 95% CI = 1.21-4.02), corticosteroid therapy (OR = 3.37, 95% CI = 1.39-8.20) and use of histamine-2 receptor antagonists (OR = 2.68, 95% CI = 1.14-6.36), while the use of neuraminidase inhibitors (OR = 0.57, 95% CI = 0.34-0.94) was protective. Neuraminidase inhibitors within the first 2 days after the influenza onset reduced hospital stay by a mean of 1.9 days (95% CI = 4.7-6.6).
CONCLUSIONS:
The use of neuraminidase inhibitors decreases the length of hospital stay and admission to intensive care and/or death.
PMID:
22467633
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/22467633